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Abstract
Background:  GABA transporter-1 (GAT-1; genetic locus SLC6A1) is emerging as a novel target for treatment of
neuropsychiatric disorders. To understand how population differences might influence strategies for pharmacogenetic studies,
we identified patterns of genetic variation and linkage disequilibrium (LD) in SLC6A1 in five populations representing three
continental groups.
Results: We resequenced 12.4 kb of SLC6A1, including the promoters, exons and flanking intronic regions in African-American,
Thai, Hmong, Finnish, and European-American subjects (total n = 40). LD in SLC6A1 was examined by genotyping 16 SNPs in
larger samples. Sixty-three variants were identified through resequencing. Common population-specific variants were found in
African-Americans, including a novel 21-bp promoter region variable number tandem repeat (VNTR), but no such variants were
found in any of the other populations studied. Low levels of LD and the absence of major LD blocks were characteristic of all
five populations. African-Americans had the highest genetic diversity. European-Americans and Finns did not differ in genetic
diversity or LD patterns. Although the Hmong had the highest level of LD, our results suggest that a strategy based on the use
of tag SNPs would not translate to a major improvement in genotyping efficiency.
Conclusion: Owing to the low level of LD and presence of recombination hotspots, SLC6A1 may be an example of a
problematic gene for association and haplotype tagging-based genetic studies. The 21-bp promoter region VNTR polymorphism
is a putatively functional candidate allele for studies focusing on variation in GAT-1 function in the African-American population.
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Background
γ-aminobutyric acid (GABA) is the most ubiquitous
inhibitory neurotransmitter in brain. Abnormal function
of the GABA system has been implicated in almost every
common neurological and psychiatric disorder. Augmen-
tation of brain GABA function is the presumed therapeu-
tic mechanism of several classes of medications, including
the benzodiazepines, gabapentin, and pregabalin, which
are used in treatment of many psychiatric and neurologi-
cal disorders, addictions, and pain [1,2]. Identifying
genetic factors responsible for variation in clinical
response holds promise as a way to improve the clinical
application of these medications; it may be possible to
identify those who are most likely to respond to treatment
and those who are at risk to develop adverse effects. For
these kinds of studies, it will be important to identify pol-
ymorphisms in genes encoding the components of the
brain GABA system. Although the HapMap project [3] will
identify the major basic blocks of linkage disequilibrium
in these genes, detailed patterns of genetic variation,
including the discovery of novel functional variants, can
only be accomplished through resequencing.
A novel class of medications was recently developed that
act by blockade of GABA transporters (GAT), thereby
inhibiting GABA uptake. Four main subtypes of GABA
transporters, the GAT-1, GAT-2, GAT-3 and Betaine/GABA
transporter-1 (BGT-1), have been identified through
molecular cloning. The first medication in the GABA
reuptake inhibitor class to become available for clinical
use was tiagabine [(-)-(R)-1-(4,4-Bis(3-methyl-2-
thienyl)3-butenyl) nipecotic acid hydrochloride], which
selectively blocks GAT-1 sites [4]. Tiagabine was devel-
oped for treatment of seizure disorders but is being used
by many psychiatrists to treat a variety of conditions in
which augmentation of brain GABA function is thought to
be desirable to alleviate clinical symptoms. Preliminary
studies suggest that tiagabine is effective in treatment of
anxiety [5], sleep disorders [6], depression [7] and addic-
tions [2,8,9]. Animal studies suggest that most of the tia-
gabine's common adverse effects, such as muscle
twitching and sedation, arise from specific inhibition of
GAT-1 [10]. Tiagabine has a rare, but serious adverse effect
– non-convulsive status epilepticus – which has raised
concerns about its off-label use in treatment of psychiatric
disorders [11]. Pharmacogenetic study could plausibly
help to identify those subjects who are at greatest risk for
developing side-effects to tiagabine and other medica-
tions that inhibit GAT-1.
The SLC6A1 gene, which encodes the GAT-1 protein, is an
obvious candidate for pharmacogenetic studies of tiagab-
ine and other GAT-1 inhibitors [12]. In anticipation of
larger pharmacogenetic studies, we aimed to identify
novel genetic variation and examine linkage disequilib-
rium in the SLC6A1 gene in five populations representing
three major continental groups [European (EA and Finn-
ish), African (AA) and Asian (Thai and Hmong)]. Popula-
tions considered isolated, Finnish and Hmong, and two
mixed populations, EA and AA, were examined, to under-
stand how population differences should influence plan-
ning for pharmacogenetic studies. By comparing isolated
and mixed populations, we hoped to shed further light on
the purported benefits of isolated populations in map-
ping complex genetic traits [13,14]. Furthermore, our goal
was to identify a set of haplotype tagging markers for stud-
ies focusing on response to GAT-1 inhibition. However,
very low levels of LD was discovered in SLC6A1 gene sug-
gesting that traditional haplotype-based approaches of
examining this gene in pharmacogenetic studies would be
of limited utility.
Results
Algorithmic promoter prediction
The sequence for SLC6A1, located in contig NT_022517,
which contains the sequence for human chromosome 3,
was used as a reference. ElDorado software [15] located
two putative SLC6A1 promoter regions in the contig at
positions 10973950–10974553 and 10998399–
10998999 (+ strand). The first region is located in an area
surrounding the boundary between the 5' region and exon
1 of SLC6A1 and isestimated to be 604 bp long. Hereafter,
we refer to this region as the upper promoter region. The
second putative promoter region of 601 bp was located in
the area flanking the boundary between intron 2 and exon
3. This region extends 70 bp across the SLC6A1  start
codon in the 3' direction in exon 3. We refer to this region
as the lower promoter region.
Nucleotide diversity in SLC6A1 in five populations
The SLC6A1 promoter regions, 16 exons, and the flanking
intronic regions were amplified and resequenced in 7–9
samples from each of the five populations. A total of 61
SNPs were found in the sequencing screening sample,
including 5 SNPs in the promoter regions, 3 synonymous
coding sequence SNPs, and 53 non-coding region SNPs.
No non-synonymous SNPs were found. The identified
SLC6A1  variants, including frequency in the screening
sample, location, and flanking sequence are provided in
the additional data file 1.
In the screening sample, 33 of the 61 SNPs discovered
(54%) were present in more than one population. More
SNPs unique to a single population or continental group
were found in the AAs than in all of the other populations
combined (counting Finns and EAs, and Thai and
Hmong, together). Sixteen population-specific SNPs were
observed in the AAs, one in the EAs, 6 in the Finnish, 4 in
the Thai, and 2 in the Hmong (see additional data file 1);
i.e., a total of 13 in the populations other than AAs. ThreeBMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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common population-specific SNPs were found in AA pop-
ulation (-24794A/G, -24126G/T and 17885 A/C, minor
allele frequencies = 0.39, 0.33 and 0.22) (These estimates
of population allele frequencies have to be interpreted
with caution since the data were derived from sequencing
only 14–18 chromosomes per population). Analysis of
nucleotide diversity based on the sequencing data indi-
cated that AAs had the greatest number of polymorphic
sites (n = 41), highest nucleotide diversity per bp (2.77 ×
10-4) and highest Watterson's estimator of theta (θ) (2.55
× 10-4). Inspection of nucleotide diversity in the Hmong,
Finnish, EA, and Thai populations revealed no marked
differences among these four populations (Table 1). As
expected, nucleotide diversity was lower in exons as com-
pared to intronic regions (πEX = 5.5–7.0 × 10-5, πINT = 1.1–
2.3 × 10-4). Interestingly, nucleotide diversity was not
higher in the AAs when exonic sequence only was consid-
ered (πAA = 5.9 × 10-5, πEA = 6.4 × 10-5, πFinn = 7.1 × 10-5,
πThai = 5.6 × 10-5, πHmong = 5.6 × 10-5). The average number
of heterozygous SNPs per person in the approximately
12.4 kb of the SLC6A1 sequence was the highest in AAs
(12.22) and was lowest in the Hmong population (3.75).
In Finns, the mean number of heterozygous SNPs was
8.63, in EAs it was 6.57, and in Thai it was 8.38 (Table 1).
The number of heterozygous SNPs differed significantly
by population (ANOVA p < 0.0001). Post hoc comparisons
showed that the Hmong had fewer heterozygous SNPs
than the other populations (each comparison p < 0.009),
with the exception of EAs (p = 0.11). AAs had more heter-
ozygous SNPs than each of the other populations (each
comparison p < 0.032).
Novel length polymorphisms in the promoter region
Two novel length polymorphisms were identified in the
upper promoter of SLC6A1. The largest, and perhaps the
more interesting polymorphism, is a 21-bp VNTR poly-
morphism, which is present either as a single element or
as two tandem repeats, hereafter referred to as the SLC6A1
short and SLC6A1 long allele, respectively. The more com-
mon SLC6A1 short allele contains an A/G SNP in its 16th
base (-24794 A/G) (Figure 1). In our sample, the A allele
of the -24794 SNP is in perfect linkage disequilibrium
with the long allele, which contains G in its 16th base. In
other words, the A allele always coincides with the long
allele.
A novel two-base-pair deletion (GG/-GG) at positions (-
24780 to -24781) was present in all 5 populations stud-
ied. This polymorphism is located only 8 bp 3' to the last
base pair of the short/long polymorphism. The -GG allele
occurs only in the context of the short allele.
The  SLC6A1  short/long and GG/-GG polymorphisms
were genotyped in 46 EA, 60 AA, 59 Thai, 47 Finnish and
48 Hmong individuals. The allele frequency of the long
allele was 0.39 in the AA sample but it was not found in
other populations. The GG/-GG polymorphism occurred
in all 5 populations. The -GG allele frequency was 0.30 in
EA, 0.23 in AA, 0.33 in Finnish, 0.22 in Thai and 0.16 in
Hmong.
Linkage disequilibrium in the SLC6A1 gene
For analysis of linkage disequilibrium in SLC6A1, a total
of 16 SNPs were genotyped in the AA, Thai, Hmong, EA,
and Finnish samples. The SNPs were selected with the
goal of encompassing the SLC6A1 gene with SNPs with
allele frequencies > 10% in most populations studied in
order to allow comparison of LD patterns between popu-
lations. Twelve of the 16 SNPs studied met this criterion.
SNP rs1710879 was virtually monomorphic in AA popu-
lation. The allele frequencies of all 16 SNPs were in
Hardy-Weinberg equilibrium (HWE). The LD structure of
the SLC6A1 gene, as detected by this set of SNPs, was eval-
uated by calculating D' and r2 using the HAPLOVIEW pro-
gram [16]. The LD structure of the SLC6A1  gene is
presented in Figure 2. Fragmentation of LD into several
poorly-defined blocks was noted in all 5 populations
studied (Figure 2). There were two short blocks of LD (D'
= 0.8–1) observed in all five populations. The first block
is located between the markers -29477 (Marker 1, Figure
2) and -24321 (Marker 2, Figure 2). The second LD block,
which is located between markers -17590 (Marker 3, Fig-
ure 2) and -9765 (Marker 5, Figure 2), was also found in
all populations studied, although the level of LD was
lower in AAs. The third LD block was observed in the EA
and Finnish populations between markers -1529 (Marker
6, Figure 2) and 3164 (Marker 8, Figure 2).
Table 1: Indices of SLC6A1 nucleotide diversity in five populations.
Populations Number of 
polymorphic sites
Nucleotide diversity per 
bp (π) (10-4)
Watterson's estimator of 
theta (θ) (10-4)
Mean number of 
heterozygous SNPs 
per person
European-American 21 1.72 1.41 6.57
African-American 41 2.77 2.55 12.22
Finnish 29 2.11 1.87 8.63
Thai 31 2.14 2.00 8.38
Hmong 24 1.62 1.55 3.75BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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In accordance with low levels of LD, Tagger identified few
haplotype tagging SNPs [17]. A SNP tagging approach
would have allowed omission of three SNPs each in the
EA, Finnish, and Thai populations and omission of two
SNPs in the Hmong population. None of the 16 SNPs
examined in the AA population was identified as a haplo-
type tagging SNP. We estimated the span of LD in differ-
ent populations using r2/distance as an index. The index
of LD span was about twofold higher in the Hmong pop-
ulation than in any of the other populations. The differ-
ences were greatest in the distance bins < 10 kb and 30–40
kb, where the median r2/distance value was two-to-three
fold higher in the Hmong than in the other populations
(Figure 3).
Haplotype diversity in SLC6A1
To further elucidate the SLC6A1 haplotype structure, we
used PHASE [18,19] to estimate haplotype frequencies in
the five populations. Consistent with the observation of
low levels of LD, no common SLC6A1 haplotypes span-
ning the entire gene were identified in any of the popula-
tions. Haplotype dispersion varied depending on the
number of SNPs included in the haplotype. When all 16
SNPs were included in the analysis, no common haplo-
types were observed. The most common haplotype had a
frequency of 0.048 in the EA, 0.039 in the AA, 0.076 in the
Finnish, 0.049 in the Thai and 0.097 in the Hmong pop-
ulations. Common haplotypes were observed when the
analysis was restricted to narrower segments of the gene,
i.e., when there were computationally fewer possibilities.
We noted that there were differences between populations
in the composition and number of common SLC6A1 hap-
lotypes. To examine this further, we reconstructed each
consecutive three-SNP haplotype in each population
using a sliding window analysis across the panel of 16
SNPs. The four most common three-SNP haplotypes in
each window and in each population were identified. We
then calculated how many times each of the common
three-SNP haplotypes in each window was disjoint (i.e.,
not shared) between the populations. A summary pair-
wise score was calculated for each of the populations,
which is presented in Table 2. For example, of all "top-
four" three-SNP SLC6A1 haplotypes, 26.8% were disjoint
between AAs and EAs.
Illustration of the 21 bp insertion/deletion polymorphism (SLC6A1 long and short alleles) and the insertion/deletion GG allele in  the SLC6A1 gene Figure 1
Illustration of the 21 bp insertion/deletion polymorphism (SLC6A1 long and short alleles) and the insertion/deletion GG allele in 
the SLC6A1 gene. Picture (A) shows position of -24794 A/G SNP, 21 bp insertion and GG deletion. Picture (B) shows the 
sequence for the SLC6A1 short and long alleles and the -24794 A/G SNP. The A allele of the -24794 always coincided with the 
long allele in our populations. Sequence for the GG insertion/deletion polymorphism is presented in picture (C).BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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Illustration of the SLC6A1 LD structure and recombination hotspots in the 5 populations Figure 2
Illustration of the SLC6A1 LD structure and recombination hotspots in the 5 populations. Upper graphs illustrate elevations 
from the background recombination rates across the SLC6A1 gene. Y axis represent recombination rate and X axis represents 
physical distance between the markers [19, 20]. In Figure A, recombination rates for HapMap CEPH Western Europeans 
(CEU) and European-Americans of the present study are presented. In Figure B, recombination rates for HapMap Yoruban 
(YRI) and African-Americans of the present study are presented. In Figure C, recombination rates for HapMap combined Han 
Chinese and Japanese populations (HCB+JPT) and the Thais of the present study are presented. In Figures D and E, recombina-
tion rates for the Finns and Hmongs of the present study are presented. In the middle, the exon-intron structure of SLC6A1 
and location of the markers is presented. LD (D') between the SNPs in SLC6A1 is illustrated in the lower triangular graphs.BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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Recombination hotspots in SLC6A1
We considered recombination hotspots as an explanation
for low level LD in SLC6A1. Recombination rates were cal-
culated for the genotype data using the -MR and -X10
options of the PHASE program [20,21] and genotype data
for all 16 SLC6A1 SNPs. Average recombination rates in
the five populations are shown in Figure 2. These data
show two areas in SLC6A1 with elevated recombination
rates. The first area is demarcated by markers -29477
(Marker 1) and -13071 (Marker 4) and the second one by
markers 7772 (Marker 9) and 20172 (Marker 15), hereaf-
ter referred to as the upper and lower hotspots, respec-
tively. There were population differences in the amplitude
of the hotspots (Figure 2). In the upper hotspot, which is
located in the areas of intron 1 and exon 1, an increase in
the recombination rate was observed in all five popula-
tions. The Hmong and AA populations showed lower rate
and width of the lower hotspot, located in the area
between exon 8 and 16, than did the EAs, Finns or Thai
(Figure 2). To further elucidate these findings, we ana-
lyzed SLC6A1 genotypes available through HapMap using
PHASE, as described above. Genotyping data for the com-
bined group of Japanese and Han Chinese, Yoruba, and
Western Europeans were analyzed and compared to our
results. We compared genotype data from our 16 SNPs
and genotype data from 27–31 SNPs in HapMap. Two sets
of SNPs, our and the HapMap SNPs, are not exactly the
same but they are all located within the SLC6A1 gene (one
dot on X-axis in Figure 2 represents one SNP). It appears
that genotype data from the two samples (the present
study and HapMap) are consistent, both showing evi-
dence for two areas of increase in recombination rate
within SLC6A1. These results support our findings (Figure
2) regarding two recombination hotspots in SLC6A1.
Discussion
The goal of the present study was to comprehensively ana-
lyze sequence variation and linkage disequilibrium in the
SLC6A1 gene in anticipation of larger pharmacogenetic
studies of tiagabine and other GAT-1 inhibitors. Rese-
quencing 12.4 kb of the SLC6A1 gene, including all 16
exons and the two putative promoter regions, revealed
numerous novel genetic variants. Perhaps the most inter-
esting polymorphism identified was a 21 bp VNTR poly-
morphism located in the upper promoter sequence of the
SLC6A1 gene (Figure 1). We have termed the alleles as the
"SLC6A1 short," which has one copy of the allele and
"SLC6A1 long," in which the allele is duplicated (Figure
1). Interestingly, the long allele was common in AAs
(39%), while in the other populations, it was absent. A
likely explanation for the lack of this allele in non-African
populations is genetic drift. However, other explanations,
such as natural selections, are also possible. Functional
studies focusing on understanding whether the short and
long allele lead to differential expression of the GAT-1
protein are clearly warranted; these studies may also help
in elucidating whether the allele frequency discrepancy
between African-Americans and other populations is due
to genetic drift or selection. Previously, a comparable pro-
moter region VNTR polymorphism was described in the
serotonin transporter gene, which is known to influence
the expression of the gene [22]. Several studies have
shown that this polymorphism partially accounts for dif-
ferences in the therapeutic response to serotonin selective
reuptake inhibitors (SSRIs) [23-26], susceptibility to
depression [27,28] and alcohol dependence [29]. The
SLC6A1  short/long is a candidate polymorphism for
moderating the response to tiagabine and susceptibility to
neuropsychiatric disorders in which GABA dysfunction
may play a role, albeit only in AA populations (and any
other populations where this variant is present).
This graph illustrates LD span (expressed as median r2) in dif- ferent populations Figure 3
This graph illustrates LD span (expressed as median r2) in dif-
ferent populations. Median r2 calculated for SNP pairs in dif-
ferent distance bins (0.1–10 kb, 10.01–20 kb etc) is 
presented.
Table 2: A summary pairwise percentage score representing the 
degree to which the four most common haplotypes were disjoint 
between the five populations.
E
A 26.8
F 16.1 26.8
T 12.7 23.6 16.3
H 26.8 23.2 30.3 17.9
EAFT H
E = European-American, A = African-American, F = Finnish, T = Thai, 
H = Hmong. For example, of all consecutive "top-four" 3-SNP SLC6A1 
haplotypes, 26.8 % were disjoint between African-Americans and 
European-Americans.BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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Genetic diversity in SLC6A1  revealed through SLC6A1
resequencing showed interesting results. Although a lim-
ited number of chromosomes was examined, certain
trends were found. First, no non-synonymous SNPs were
discovered in the 80 chromosomes sequenced, suggesting
that the coding sequence of SLC6A1 has been conserved
against common amino-acid altering substitutions
through active background selection. Consistent with
these results, the nucleotide diversity was much lower in
the SLC6A1 exons compared to the intronic regions exam-
ined [30-32]. Comparison of the sequence data between
populations revealed higher nucleotide diversity in AAs
than in other populations (Table 1). In accordance with
these data, the only population in which we found com-
mon population specific SNPs, were AAs. In exons, how-
ever, nucleotide diversity was no higher in the AA
population than in the other populations. In other popu-
lations, the SNPs observed in only one population were
rarer. Although Finns and Hmong are considered to be
isolated populations, nucleotide diversity in these two
populations was not different from that observed in EAs
or Thais. Overall, no major differences in nucleotide
diversity were observed among the Hmong, Thai, EA, and
Finnish populations. Together, these findings most likely
reflect the older age of the African population relative to
the other populations, which had allowed more intronic
variation to accumulate in this population, founder
effects in non-African populations, and selection pressure
conserving the SLC6A1  exonic sequence. The extent of
conservation of GAT-1 amino acid sequence suggests an
important role of this protein in normal brain function.
The Hmong had a significantly lower number of hetero-
zygous SNPs in comparison to the other populations. One
explanation for this finding is that the Hmong subjects
may have been distantly related. We postulate that differ-
ences in the degree and age of population bottlenecks
between the Hmong and the other populations are less
likely explanations for the lower heterozygosity observed
in the Hmong; we feel that this explanation is less likely
because all non-African populations had a low observed
frequency of population-specific SNPs and because
Hmong nucleotide diversity was not significantly lower
than that of the other non-African populations [33]. A
caveat of this study is that the sample size per ethnicity
was small. Consequently, rare non-synonymous SNPs,
specific to a population, would have not been identified.
It may be useful to resequence larger samples to identify
these kinds of variations, at least in the primary target
populations of clinical trials. Laboratory methods estab-
lished for the present study should facilitate such analy-
ses. Another limitation of the study is that the
resequencing effort focused on exons. If deep intronic var-
iation in SLC6A1 contributes to functional variation at the
protein level, those variants would have been missed in
the present study. A low level of LD in SLC6A1  was
observed in all five populations (Figure 2). Consistent
with these results, in the EA, Thai, Hmong, and Finnish
populations, only two or three haplotype tagging SNPs in
the areas of preserved LD were identified. In the AAs, no
haplotype tagging SNPs were found in the 16 SNPs geno-
typed. These results suggest that very dense SNP panels
would be required to capture common variation in this
gene. Using r2/distance as the index, a longer LD span was
observed in the Hmong population than in the other pop-
ulations (Figure 3). However, higher LD probably would
not translate to significant practical improvement in gen-
otyping efficiency overall, because there were no major
differences in the number of haplotype blocks in Hmong
than in the Finnish, Thai and EA populations. Consider-
ing the low level of LD, SLC6A1 may pose special chal-
lenges for association studies both in isolated and mixed
populations. The common SLC6A1  3-SNP haplotypes
were largely the same in the five populations (Table 2),
but were not completely overlapping. These results sug-
gest a certain degree of, but not absolute, portability of
SNP genotyping sets between the populations. It would
interesting to study larger EA, AA, Hmong, Thai and Finn-
ish population samples to further refine the structure and
frequencies of the common overlapping and population-
specific haplotypes [34]. In addition, it will be interesting
to study whether haplotype and SNP profile characteris-
tics, such as absence of common non-synonymous substi-
tutions extends to patient populations suffering from
various neuropsychiatric disorders, which were not stud-
ied here. The present study primarily focused on non-clin-
ical samples and therefore no data were available to
assesses whether disease associated variants are present in
human populations.
Intrigued by these findings, we examined whether recom-
bination hotspots could explain low levels of LD in
SLC6A1. Two hotspots were identified using PHASE; the
first is located in the areas of exon 1 and intron 1. The sec-
ond hotspot is located in the area demarcated by exons 8
and 16. As expected, within the hotspots, D' fell off rap-
idly. For example, in the Finns, in the area of the distal
hotspot, D' was only 0.184 between markers 12 and 13,
which are spaced 107 bp apart and D' was 0.044 between
13 and 14, which are spaced 489 bp apart. Areas of high
recombination, such as seen in SLC6A1, potentially limit
large-scale association studies, as it would be exception-
ally difficult to find risk alleles relying on linkage disequi-
librium if the alleles were located inside a recombination
hotspot.
Conclusion
SLC6A1 is a complicated target for pharmacogenetic stud-
ies because low levels of LD and recombination hotspots
would make it difficult to establish an association
between genetic markers and response to GAT-1 modula-BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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tion. Furthermore, our study suggests that focusing on iso-
lated populations, such as Finns or Hmong, would not
provide major benefits to genotyping efficacy of SLC6A1.
An interesting 21-bp VNTR polymorphisms (SLC6A1
short and SLC6A1 long) was discovered in the promoter
sequence of the SLC6A1 gene, which is common in Afri-
can-Americans. This new polymorphism is a novel candi-
date for studies focusing on genetically influenced
differences in GAT-1 expression, and hence, response to
medications that inhibit GAT-1 function.
Methods
DNA samples
For re-sequencing of the SLC6A1 gene, 40 genomic DNA
samples were collected from unrelated individuals repre-
senting 5 different populations: EA (n = 7), AA (n = 9),
Finnish (n = 8), Thai (n = 8), and Hmong (n = 8). The
Finnish subjects were unrelated parents of adolescent sub-
jects who were participating in an epidemiological study
focusing on the identification of risk factors for early-
onset mental illness and substance dependence in Finland
[35]. The Thai and Hmong populations were collected in
Thailand as part of an ongoing genetic association and
population genetic study. The Thais selected for rese-
quencing had grandparents and parents of Thai ancestry
(Thai-Thai) or had mixed Thai and Chinese ancestry
(Thai-Chinese), by subject report. These samples were
obtained from a blood drive in Bangkok, Thailand. The
Hmong subjects were recruited in a Hmong village in the
northern part of Thailand. The AA and EA samples have
been described earlier elsewhere [36]. Both EA and AA
samples were self-identified and confirmed as such by
Bayesian marker clustering [36]. All subjects provided
informed consent as approved by the appropriate institu-
tional review boards. In addition, 46 EA, 60 AA, 59 Thai,
47 Finnish and 48 Hmong individuals were genotyped for
16 SLC6A1 SNPs to examine linkage disequilibrium (LD)
in this gene. The Thai subjects selected for examination of
linkage disequilibrium were Thai-Thai. Recruitment and
population characteristics of subjects selected for SLC6A1
genotyping were identical of subjects selected for rese-
quencing [35,36]. The participants were recruited from
non-clinical populations. No detailed medical informa-
tion was available for most of the participants. Therefore
biases deriving from undetected medical conditions of the
control sample could not be controlled. All studies
described in this article were conducted according to the
Declaration of Helsinki. The studies were approved by the
institutional review boards of Yale University School of
Medicine, West Haven VA Hospital, Northern- Ostroboth-
nia Hospital District (University of Oulu, Finland) and
Chulalongkorn University (Bangkok, Thailand). All sub-
jects signed a written informed consent for participation
in this study.
Promoter prediction
The ElDorado program of the Genomatix software pack-
age was used to predict the location of the SLC6A1 pro-
moter region [15]. The sequence of the SLC6A1  gene
submitted to the promoter region analysis was obtained
from the National Center for Biotechnology Information
(NCBI) [37].
Amplification and sequencing
For sequencing of SLC6A1, the upper and lower promoter
regions, all 16 SLC6A1 exons (total of 4.4 kb) and 7.3 kb
of flanking intronic regions were amplified. About 70 bp
of the predicted 601 bp of the lower promoter region were
not included in the sequence analysis. Approximately
12.4 kb of the SLC6A1 gene was amplified, corresponding
to about 25% of the total length of the gene. All primers
were designed with the PRIMER3 software [38]. Primers
were obtained from Invitrogen (Carlsbad, CA). PCR
amplification was optimized before sequencing by testing
different cycling conditions. Betaine (Sigma Aldrich, St.
Louis, MO) at 0.5–1 M final concentrations was added to
the reactions, as needed, to enhance specificity and yield
of PCR amplification. PCR reactions were carried out in
15 µl volumes containing 20 ng genomic DNA, 200 µM of
dNTPs mix (Stratagene, La Jolla, CA), 1 µM of mixed
primers forward and reverse, 1X PC2 buffer, 0.75 U of
KlenTaq1™ (Ab Peptides, St Louis, MO) and 0.5–1 M
betaine when needed. Thermocycling conditions con-
sisted of an initial denaturation step at 95°C for 5 min, 30
cycles of denaturation step at 95°C for 30 sec, an anneal-
ing step at 60–65°C 30 sec, and an extension step at 72°C.
The duration of the extension step varied from 30 sec to 2
min depending on the length of the amplicon. After opti-
mization, genomic DNA samples from each population
were PCR amplified followed by purification with MinE-
lute PCR purification columns (Qiagen, Valencia, CA) or
the reaction mixtures were treated with ExoSAP-IT (USB,
Cleveland, OH) to remove excess nucleotides and prim-
ers. Purified PCR samples were sequenced in the forward
and reverse directions at Yale University W.M Keck Foun-
dation Biotechnology Resource Laboratory. Sequencing
reactions were conducted using the BigDye Terminator
v3.1 cycle sequencing kit and an ABI 9800 Thermocycler
(Applied Biosystem, Foster city, CA). Sequencing reac-
tions were analyzed on an ABI 3730 xl DNA Analyzer
(Applied Biosystems, Foster city, CA). Owing to technical
problems, approximately 300 bp in exon 7 and intron 8
(2.4% from total 12.4 kb sequenced region) is missing in
the sequencing data in Thai and Hmong populations (see
additional data file 1).
Owing to the repeat elements contained in the identified
upper promoter sequence and homologous sequences
within the SLC6A1, the upper promoter region and parts
of exon 1 were amplified using nested PCR. In addition,BMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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for amplification of a 180 bp fragment located in the junc-
tion of the 5' upstream region and exon 1, a region which
is very high in CG content, 7-deaza-dGTP (New England
BioLabs, Beverly, MA) was added to the reactions.
Genotyping and linkage disequilibrium study
A total of 16 SNPs were chosen for genotyping in popula-
tion samples to examine haplotype structure of the
SLC6A1  gene. Nine SNPs chosen for genotyping were
identified through resequencing: -24321A/C, -1529A/G,
949A/G, 3164C/T, 14351A/G, 16009A/G, 16116C/T,
20172C/T and 20622A/G. The remaining seven SNPs, -
29477C/T, -17590C/T, -13071A/G, -9765C/T, 7772A/G,
13269C/T, and 16605C/T, were chosen from the NCBI
dbSNP [39] collection. Of the 16 SNPs studied, 14 were
available through Applied-Biosystem's Assay-On-
Demand service (Applied Biosystems, Foster city, CA).
One assay was custom designed and obtained through the
ABI's Assay-by-Design service (Applied Biosystems, Foster
city, CA). PCR amplification of the 5' nuclease assays were
conducted using 1 ng of DNA, 1X TaqMan universal PCR
master mix (Applied Biosystems, Foster city, CA), 0.5X
SNP genotyping assay mix [Applied Biosystems, Foster
city, CA]. PCR conditions were as follows: denaturation
step of 95°C for 10 min, followed by 50 cycles of 95°C for
15 sec and 60°C for 1 min. Amplification was performed
on PTC-200 cyclers (MJ Research, Hercules, CA) and data
were analyzed using the ABI Prism 7900HT Sequence
Detector System and software version 2.1 (Applied Biosys-
tem, Foster city, CA). All samples were run in duplicate for
quality control purposes. Based on comparison of the
duplicate runs, we estimated the genotyping error rate to
be less than 0.05%. The -24321A/C SNP was genotyped
using 7-deaza-dGTP sequencing because its location
inside a GC-rich region made it very difficult to design a 5'
nuclease assay for this SNP.
Genotyping of the length polymorphisms
Amplification of the region containing the 21 bp short/
long VNTR and 2 bp GG/-GG insertion/deletion polymor-
phisms was accomplished using primers 5'AAGGAGAGA-
GATTGGAGCG 3' and 5'CTTCTTTCCTCTCGCATTC 3'
(Invitrogen, Carlsbad, CA). PCR reactions were conducted
in 15 µl volumes containing 20 ng genomic DNA, 200 µM
of dNTPs mix (Stratagene, La Jolla, CA), 1 µM of mixed
reverse and forward primers, 1X PC2 buffer, 0.75 U of
KlenTaq1™ (Ab Peptides, St Louis, MO) and 1 M Betaine.
The thermocycling conditions consisted of an initial step
at 95°C for 5 min, 30 cycles of denaturation at 95°C for
30 sec, annealing 60°C 30 sec, and extension 72°C 30 sec.
The lengths of the PCR products corresponding to the
long and short alleles are 166 bp and 145 bp. The long
and short alleles were separated using 3% metaphore aga-
rose and gel electrophoresis (ISC BioExpress, Kaysville,
UT). The GG/-GG insertion/deletion polymorphism was
genotyped using direct sequencing of the PCR product as
described in above.
Statistical analysis
Indices of sequence variation in SLC6A1 were calculated
using a web application SLIDER [40]. These indices
included the number of polymorphic sites, nucleotide
diversity per base pair (π) and the Watterson's estimator
of theta (θ). Nucleotide diversity per base pair (π)
describes the mean number of differences per site between
two sequences chosen at random from a sample of
sequences. The Watterson's estimator of theta (θ) is the
observed number of SNPs adjusted for the sample size
and new mutation rate expected to occur in each genera-
tion [41]. In addition, for each subject we calculated the
number of heterozygous SNPs observed in the sequence
data. The number of heterozygous SNPs was compared
between populations using ANOVA followed by post hoc
Fisher's Least Significant Difference-test.
PHASE software, which implements a Bayesian algorithm
for haplotype reconstruction, was used to estimate haplo-
type frequencies [18,19]. PHASE's options -X10 and -MR
were used to estimate recombination rates across SLC6A1
[20,21]. The value on the Y-axis of Figure 2 shows changes
in recombination parameter (ρ) per base pair of SLC6A1
exceeding the background recombination rate [20,21].
The average recombination rate was estimated based on
1,000 burn-ins and 1,000 iterations. Recombination fre-
quencies at SLC6A1 were compared visually between our
and HapMap data. No statistical analyses were performed.
To evaluate haplotype diversity among populations, we
studied how often the most common haplotypes were
shared or disjoint. The haplotypes were identified using a
sliding window analysis across every three consecutive
SLC6A1 SNPs. The four most common three-SNP haplo-
types in each window and in each population were iden-
tified. The rationale for choosing the four most common
haplotypes for this analysis was that visual inspection of
the haplotype frequencies told us that in each window
and in each population virtually all variation in haplotype
diversity was captured by the four most common haplo-
types. The average percent of all haplotypes captured by
the top four haplotypes was 96%. We then calculated how
many times each of the common three-SNP haplotype
was disjoint between the populations. A summary pair-
wise score derived for the populations is presented in
Table 2.
LD patterns in SLC6A1 were visualized using HAPLOV-
IEW version 3.2[16] We used the Tagger algorithm, imple-
mented in HAPLOVIEW, to search for haplotype tagging
SNPs in SLC6A1. [17] We used the default Tagger thresh-
olds r2 > 0.8 and LOD score > 3. POWERMARKER [42]
was used to calculate allele frequencies and examinationBMC Genetics 2007, 8:71 http://www.biomedcentral.com/1471-2156/8/71
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of Hardy-Weinberg equilibrium (HWE). To illustrate dif-
ferences in the span of LD in the five populations, r2 was
plotted against physical distance. To do this, r2 was calcu-
lated for all SNP pairs. Because these values were not nor-
mally distributed, median values are presented. Physical
distance (bp) was divided into distance bins to illustrate
population differences in LD span across a range of phys-
ical distances. Median r2 in distance bins (0.1–10 kb,
10.01–20 kb etc) in different populations is presented in
Figure 3. No statistical analyses were performed on these
data. Software CENSOR was used to search for repeat ele-
ments within the recombination hotspots [43,44].
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